Evidence map›Paper›PMID 22361264›Full record

ArticlePhysiology & behavior2012

The orexin-1 receptor antagonist SB-334867 decreases sympathetic responses to a moderate dose of methamphetamine and stress.

Daniel E Rusyniak, Dmitry V Zaretsky, Maria V Zaretskaia, Pamela J Durant, Joseph A DiMicco

Open access · greenAbstract read
In one paragraph

Article in Physiology & behavior, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Orexin and Central Modulation of Cardiovascular and Respiratory Function.Current topics in behavioral neurosciences · 2017
    Review
  10. Article
  11. Review
  12. Article
  13. Meth math: modeling temperature responses to methamphetamine.American journal of physiology. Regulatory, integrative and comparative physiology · 2014
    Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Daniel E RusyniakDepartment of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States. drusynia@iupui.edu
Dmitry V Zaretsky
Maria V Zaretskaia
Pamela J Durant
Joseph A DiMicco
Indiana University School of MedicineIndiana University – Purdue University Indianapolis · US

Funding

CNS circuitry and receptors mediating the effects of MDMAR01DA026867 · NIDA · INDIANA UNIVERSITY INDIANAPOLIS · PI RUSYNIAK, DANIEL E · 2010 to 2014
$1.6M
Ecstasy and the Dorsomedial HypothalamusK08DA020484 · NIDA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI RUSYNIAK, DANIEL E · 2006 to 2010
$906k
NIDA NIH HHS DA020484NIDA NIH HHS DA026867NIDA NIH HHS K08 DA020484NIDA NIH HHS R01 DA026867
6 · The paper itself

Abstract

We recently discovered that inhibiting neurons in the dorsomedial hypothalamus (DMH) attenuated hyperthermia, tachycardia, hypertension, and hyperactivity evoked by the substituted amphetamine 3, 4-methylenedioxymethamphetamine (MDMA). Neurons that synthesize orexin are also found in the region of the DMH. As orexin and its receptors are involved in the regulation of heart rate and temperature, they would seem to be logical candidates as mediators of the effects evoked by amphetamines. The goal of this study was to determine if blockade of orexin-1 receptors in conscious rats would suppress cardiovascular and thermogenic responses evoked by a range of methamphetamine (METH) doses. Male Sprague-Dawley rats (n=6 per group) were implanted with telemetric transmitters measuring body temperature, heart rate, and mean arterial pressure. Animals were randomized to receive pretreatment with either the orexin-1 receptor antagonist SB-334867 (10mg/kg) or an equal volume of vehicle. Thirty minutes later animals were given intraperitoneal (i.p.) injections of either saline, a low (1mg/kg), moderate (5mg/kg) or high (10mg/kg) dose of METH. Pretreatment with SB-334867 significantly attenuated increases in body temperature and mean arterial pressure evoked by the moderate but not the low or high dose of METH. Furthermore, animals treated with SB-334867, compared to vehicle, had lower temperature and heart rate increases after the stress of an i.p. injection. In conclusion, temperature and cardiovascular responses to a moderate dose of METH and to stress appear to involve orexin-1 receptors. The failure to affect a low and a high dose of METH suggests a complex pharmacology dependent on dose. A better understanding of this may lead to the knowledge of how monoamines influence the orexin system and vice versa.

Indexed as

AnimalsBenzoxazolesBlood PressureBody TemperatureDose-Response Relationship, DrugGABA-A Receptor AgonistsMaleMethamphetamineMuscimolNaphthyridinesOrexin ReceptorsRatsRats, Sprague-DawleyReceptors, G-Protein-CoupledReceptors, NeuropeptideStress, Psychological1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl ureaBenzoxazolesGABA-A Receptor AgonistsMethamphetamineMuscimolNaphthyridinesOrexin ReceptorsReceptors, G-Protein-CoupledReceptors, NeuropeptideUrea

Identifiers

PMID22361264
PMCPMC3371311
OpenAlexW2012165012

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.